Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa

Levodopa (LD) administered with dopa decarboxylase inhibitor is predominantly metabolized in the periphery by catechol-O-methyltransferase (COMT) to 3-O-methyldopa (3-OMD). Catechol-O-methyltransferase inhibition can improve treatment outcomes by decreasing variability in circulating LD concentratio...

Descripción completa

Detalles Bibliográficos
Autores principales: LeWitt, Peter, Liang, Grace S., Olanow, C. Warren, Kieburtz, Karl D., Jimenez, Roland, Olson, Kurt, Klepitskaya, Olga, Loewen, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010692/
https://www.ncbi.nlm.nih.gov/pubmed/36688497
http://dx.doi.org/10.1097/WNF.0000000000000538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010692/
https://www.ncbi.nlm.nih.gov/pubmed/36688497
http://dx.doi.org/10.1097/WNF.0000000000000538

Ejemplares similares